HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study Provides "Reassurance" That Sunscreen Use Reduces Melanoma Risk

This article was originally published in The Rose Sheet

Executive Summary

Regular sunscreen use can help prevent melanoma, the most serious form of skin cancer, suggests a study published online Dec. 6 in the Journal of Clinical Oncology.

You may also be interested in...



ACSH’s 2011 “Unfounded Scares” List Includes Sunscreen, Fragrance

The American Council on Science and Health names several items that are or are in personal-care products to its annual list of “Unfounded Health Scares.” Substance dosage and animal testing’s relevancy to human health effects were two common factors characteristic of many of the year’s scares.

Physician-Led Nanodermatology Society Endorses Nano-Sunscreens

With the summer months looming, the Nanodermatology Society announces findings from its scientific literature review, maintaining that nanotechnology in sunscreen products poses no serious health risks to consumers – certainly not in proportion to the dangers of unprotected sun exposure.

Physician-Led Nanodermatology Society Endorses Nano-Sunscreens

With the summer months looming, the Nanodermatology Society announces findings from its scientific literature review, maintaining that nanotechnology in sunscreen products poses no serious health risks to consumers – certainly not in proportion to the dangers of unprotected sun exposure.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel